Navigation Links
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
Date:6/2/2008

who have failed standard hormonal therapies. The dose-expansion study has enrolled 84 patients in three cohorts (60, 150, 240 mg/day) to date. Dr. Scher's presentation covered PSA data from all patients who have been followed for at least 12 weeks, the standard minimum duration of observation used to assess the treatment effects of prostate cancer drugs. Of the 42 chemo-naive and 31 post-chemotherapy evaluable patients across the three dose levels, 23 patients (55 percent) and 13 patients (42 percent) showed PSA declines greater than 50 percent at week 12 compared to baseline, respectively. Of the 28 evaluable patients from the 240 mg/day dose group of the trial, eight patients (29 percent) experienced a decline in PSA levels of greater than 90 percent compared to 9 percent and 13 percent in the 60 mg/day and 150 mg/day dose groups, respectively.

The number of CTC in a blood sample from a prostate cancer patient can indicate prognosis; patients with higher CTC counts (greater than or equal to five) are thought to have less favorable prognoses. MDV3100 treatment preserved favorable prognosis CTC counts below five in 92 percent of patients in the 60 and 150 mg/day dose groups and converted CTC counts from unfavorable to favorable prognoses in 33 percent of patients in the 60 mg/day dose group and in 56 percent of patients in the 150 mg/day dose group, respectively.

Importantly, radiographic data from both the 60 mg/day and 150 mg/day dosing cohorts showed stabilization of disease through 12 weeks of treatment. Of the 15 evaluable patients with soft tissue disease, 12 patients (80 percent) had stabilization of disease. Prior to enrollment in this study, all these patients had progressive disease despite standard-of-care hormonal therapies, and in roughly half the patients, also chemotherapy. As opposed to most previous studies in CRPC that have used the RECIST criteria to define evaluable patients and assess radiographic changes, the MDV3100 data were ana
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
2. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
5. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
8. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
11. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... WASHINGTON , July 29, 2014 New ... in Medicare Part D by a projected $2.9 to ... by the actuarial firm Milliman released today by the ... Part D premiums could increase by as much as ... hepatitis C drugs, including Sovaldi and Olysio. ...
(Date:7/29/2014)... Conn. , July 29, 2014 Numotion,s Board ... Mike Swinford will be the company,s new Chief ... highly successful 22-year career at GE where he worked primarily ... in annual revenue to over $5 billion. His most recent ... Services. "I am thrilled to join Numotion," ...
(Date:7/29/2014)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its ... 2014 Clinical Lab Expo today by unveiling two booths ... is partnering with customers to redefine the value of ... day that they,re looking for a partner to help ... and offices," said Jack Phillips , president and ...
Breaking Medicine Technology:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Numotion Names Mike Swinford CEO 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... Oct. 26 Florida-based MEI Development Corporation, a ... acquired Georgia-based Oncology Business Advisory Group (OBAG) and ... as head of MEI Oncology Services.  MEI is ... industries, providing complete management of all aspects of ...
... Develop... -- INGELHEIM, Germany and ROCKVILLE, Md., Oct. 26 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:MEI Development Acquires Oncology Group; Names Founder as Head of Oncology Division 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 3Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 4Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 5Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 6Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 7Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 8Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 9Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 10
(Date:7/30/2014)... Sacramento, CA (PRWEB) July 30, 2014 ... Hemp Oil infused products, is pleased to announce that ... even wider selection of top quality products available for ... industry is still in it's infancy stages," site founder ... there are already a wide variety of unique products ...
(Date:7/30/2014)... The Independent Woman , a ... 5 free financial workshops in the San Francisco area ... of these workshops is our collective success, linking arms ... empowerment. , These workshops were designed by women, for ... investor, entrepreneur, and bestselling author (Rich Woman and It’s ...
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... Seattle, Wa (PRWEB) July 30, 2014 According ... by Vkool.com, this is a comprehensive guide that will help ... quickly within a few weeks. This book uncovers to readers ... candida infection. In addition, inside this book, people will discover ... yeast infection such as itching, burning, and irritation of ...
(Date:7/30/2014)... WA (PRWEB) July 30, 2014 ... availability of over 80 different electronic therapy note ... on tablets and other computing devices all while ... therapy notes or electronic medial records (EMR) consist ... evaluations, and other essential categories. SOAP and ...
Breaking Medicine News(10 mins):Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 2Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 3Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 2Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2
... April 2, 2008 InterMedia, a,Washington, D.C.-based research, ... nationwide survey of Afghanistan that finds,low awareness and ... and access to media are important predictors for ... AIDS Awareness in Afghanistan include:, -- Only ...
... ACM, a leading healthcare,benefits management ... with Carolina,Crescent Health Plan that will ... claim adjudication, and provider network management ... Through ACM,s comprehensive Managed Medicaid Assist(SM) ...
... of Molecular Imaging (AMI), the American College of Radiology ... release of significant data from the National Oncologic PET ... emission tomography (PET) in the diagnosis of cancer. ... et al. published March 24 online in the Journal ...
... Mrs. Jane M. Knight, of,Hampton, Virginia, has ... for her outstanding contributions and achievements in the,field ... About Mrs. Jane M. Knight, Mrs. ... education and women,s health. She was Nurse-Midwife with ...
... HARBIN, China, April 2, 2008 /Xinhua-PRNewswire-FirstCall/ -- China Sky,One ... or "the,Company"), a manufacturer, marketer and distributor of pharmaceutical,medicinal ... for the fourth quarter and fiscal year ended December ... Total revenues increased to $12.7 million, up 223% from ...
... Mayo Clinic researchers who study the role nanoparticles may play ... kidney stones, will lead a symposium on how these super-small ... place April 8 at the Experimental Biology conference in San ... bacteria, E. coli, but recent advances in microscopy have allowed ...
Cached Medicine News:Health News:Education and Media Key to Improving HIV/AIDS Awareness and Knowledge Levels in Afghanistan, New InterMedia Report Says 2Health News:Education and Media Key to Improving HIV/AIDS Awareness and Knowledge Levels in Afghanistan, New InterMedia Report Says 3Health News:ACM's Managed Medicaid Assist Program to Enhance Care Delivered to Carolina Crescent Health Plan Members 2Health News:SNM congratulates NOPR and its supporting organizations on successful conclusion of project 2Health News:Jane M. Knight Recognized By Strathmore's Who's Who Worldwide Publication 2Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 2Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 3Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 4Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 5Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 6Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 7Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 8Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 9Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 10Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 11Health News:Symposium to explore role nanoparticles may play in disease 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: